National Centre
for the Replacement
Refinement & Reduction
of Animals in Research

Pathways-based approaches across the biosciences: Towards application in practice

Thursday 28 April 2016, Central London

Agenda	
08.30 – 09.00	**Registration**
09.00 - 09.10	**Professor Ian Kimber** (Chair), University of Manchester, UK *Welcome and introduction*
09.10 – 9.20	**Dr Fiona Sewell**, NC3Rs, UK *3Rs benefits and potential applications of pathways-based approaches for pharmaceutical and chemical safety assessment*
Case studies: practical applications of pathways-based approaches	
9.20 – 10.15	**Dr James Sidaway**, Phenotox, UK *Comprehensive target screening by label-free cell microarray profiling to reduce animal efficacy and toxicology studies in drug discovery* **Dr Chantal Smulders**, Shell, Netherlands and **Dr Marjolein Wildwater**, Universiteit Utrecht, Netherlands *Application of non-mammalian assays in the prediction of developmental and reproductive toxicity potential to mammals*
10.15 – 10.45	**REFRESHMENTS**
10.45– 12.00	**Dr Dries Knapen**, Universiteit Antwerpen, Netherlands *An alternative testing strategy for the fish early life-stage (FELS) test - narcosis* **Dr Sylvia Escher**, Fraunhofer Institute for Toxicology and Experimental Medicine, Germany *The application of AOPs in read-across approaches* **Dr James Wheeler**, Dow AgroSciences, UK *Adverse Outcome Pathways (AOPs) focusing on endocrine active chemicals*
12.00 – 13.00	**LUNCH and poster viewing**
Adverse outcome pathways: perspectives for future development and application	
13:00-14:20	**Dr Magdalini Sachana**, OECD, France *The OECD framework* **Dr Elisabet Berggren**, EU Joint Research Centre, Italy *Lessons learned from SEURAT*

	Dr Hennicke Kamp, BASF, Germany on behalf of the EU-ToxRisk consortium *Introduction to EU-ToxRisk* **Professor Alan Boobis**, Imperial College London, UK *Perspective on next steps for application in practice*
14.20 – 14.40	**REFRESHMENTS**
Next steps to enable wider application of pathways-based approaches	
14.40 – 16.00	**Dr Carl Westmoreland,** Unilever, UK *The importance of exposure considerations* **Dr John Paul Gosling,** University of Leeds, UK *Dealing with uncertainty and increasing confidence when applying mathematical models in AOP-led risk assessments* **Dr Maurice Whelan,** European Joint Research Commission, Italy *Integrated approaches to testing and assessment* **Dr Colin Wilde,** AvantiCell, UK *The drivers and benefits of standards for* in vitro *assays: an SME perspective*
16.00 – 16.15	**REFRESHMENTS**
Keynote presentation	
16.15 – 17.00	**Dr Kevin Crofton**, National Center for Computational Toxicology, EPA, USA *The future potential of using pathways-based approaches in high-throughput quantitative human health assessments*
Roundtable discussion	
17.00 – 17.45	**The big conundrum – what constitutes validation?** Moderated by Dr Natalie Burden, NC3Rs; supported by the NAT SIG **Prof Alan Boobis**, Imperial College London, UK **Dr Kevin Crofton**, EPA, USA **Dr David Jones,** Medicines and Healthcare products Regulatory Agency, UK **Professor Ian Kimber**, University of Manchester, UK **Dr Carl Westmoreland,** Unilever, UK **Dr Maurice Whelan**, European Joint Commission, Italy **Dr James Wheeler**, Dow AgroSciences, UK
Wrap-up and close of meeting	
17.45 – 18.00	**Professor Ian Kimber**
Networking reception	
18.00 – 19.00	Drinks reception supported by the NAT SIG